Effects of prasugrel, a novel P2Y12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseases
Taketoshi Ogawa(Biomedical Research Laboratories (United States)), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Fumitoshi Asai(Azabu University), Masami Hashimoto(Daiichi-Sankyo (Japan)), Y. Niitsu(Daiichi-Sankyo (Japan)), Ken‐ichi Otsuguro(Hokkaido University), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Yoshiro Tani(Daiichi-Sankyo (Japan))
Cited by 16
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617